Ozempic face? Botox boom boosted by 'sagging face' trend, Swiss firm says
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
The trend of "Ozempic face" refers to the facial volume loss and sagging skin that some individuals experience as a side effect of using GLP-1 medications, such as Ozempic, for weight loss. This has created a new opportunity for aesthetics companies to offer treatments that address this issue, including facial fillers and other cosmetic procedures. As a broker, it's essential to consider the potential impact of this trend on the aesthetics industry and the companies that operate within it.
The Swiss firm's comments suggest that they are positioning themselves to capitalize on this trend, and investors should take note of the potential for increased demand for their services. The use of GLP-1 medications is becoming increasingly popular, and as more people experience the side effects of facial volume loss, the demand for treatments to address this issue is likely to grow. This could lead to increased revenue for aesthetics companies that offer these treatments, making them a potentially attractive investment opportunity.
As the use of GLP-1 medications continues to grow, brokers should watch for increased demand for aesthetics treatments that address facial volume loss. Companies that offer these treatments, such as facial fillers and other cosmetic procedures, may see an increase in revenue and could be a good investment opportunity. Additionally, brokers should monitor the overall trend of the aesthetics industry and how it is impacted by the growing use of GLP-1 medications, as this could have broader implications for the industry as a whole.
Originally reported by cnbc.com. BrokerNews adds analysis for finance & markets readers.